Atosiban

Drug Profile

Atosiban

Alternative Names: Antocile; Antocin; Antocin II; CAP 440; CAP 476; deTVT; dTVT; F 314; ORF 22164; RWJ 22164; Tractocile

Latest Information Update: 08 Nov 2006

Price : $50

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Ferring Pharmaceuticals; University of Turin
  • Class Tocolytics
  • Mechanism of Action Oxytocin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Preterm labour
  • Discontinued Cancer

Most Recent Events

  • 21 Jul 2001 A study has been added to the adverse events and Women's Health therapeutic trials sections
  • 03 Jul 2000 Three multicentre studies have been added to the Women's Health therapeutic trials section ,,
  • 27 Jun 2000 Launched for Preterm labour in United Kingdom (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top